review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Rachel L. Batterham | Q57033016 |
P2093 | author name string | William R Scott | |
P2860 | cites work | Medical Consequences of Obesity | Q22241663 |
Body-Mass Index and Mortality among 1.46 Million White Adults | Q22250878 | ||
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects | Q22250885 | ||
The genetic contribution to non-syndromic human obesity | Q22251027 | ||
Increases in morbid obesity in the USA: 2000-2005 | Q22251191 | ||
Endoplasmic reticulum stress and the inflammatory basis of metabolic disease | Q24633352 | ||
An obesity-associated gut microbiome with increased capacity for energy harvest | Q27860515 | ||
Inhibition of food intake in obese subjects by peptide YY3-36 | Q28204942 | ||
Vagotomy dissociates short- and long-term controls of circulating ghrelin | Q28206897 | ||
Central obesity and increased risk of dementia more than three decades later | Q28274012 | ||
Systematic review: an evaluation of major commercial weight loss programs in the United States | Q28300926 | ||
Prevalence of overweight and obesity in the United States, 1999-2004 | Q28305811 | ||
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery | Q29614192 | ||
Dynamics of fat cell turnover in humans | Q29615688 | ||
Biology of incretins: GLP-1 and GIP | Q29617302 | ||
Central nervous system control of food intake and body weight | Q29619020 | ||
A role for ghrelin in the central regulation of feeding | Q29620403 | ||
Obesity and the human microbiome | Q30052740 | ||
Role of neuropeptides in appetite regulation and obesity--a review. | Q30356494 | ||
Drug treatments for obesity: orlistat, sibutramine, and rimonabant. | Q30359088 | ||
Peptide YY: food for thought. | Q30375395 | ||
Gut hormones: implications for the treatment of obesity. | Q30378465 | ||
Comparison of competitive radioimmunoassays and two-site sandwich assays for the measurement and interpretation of plasma ghrelin levels | Q30432520 | ||
Bariatric surgery: a systematic review and meta-analysis | Q30769299 | ||
The environment within: how gut microbiota may influence metabolism and body composition | Q33696549 | ||
Effect of gastric bypass surgery on the incretins | Q33743998 | ||
Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels | Q33752066 | ||
Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? | Q33789529 | ||
Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding | Q33879265 | ||
The medical risks of obesity | Q33888248 | ||
Sleeve gastrectomy induces loss of weight and fat mass in obese rats, but does not affect leptin sensitivity | Q33905715 | ||
Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery | Q33959262 | ||
Metabolic/bariatric surgery Worldwide 2008. | Q34020011 | ||
Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes | Q34032014 | ||
Decreased dopamine type 2 receptor availability after bariatric surgery: preliminary findings | Q34079702 | ||
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans | Q34085069 | ||
Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin | Q34094232 | ||
Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. | Q34095151 | ||
Minireview: Inflammation and obesity pathogenesis: the hypothalamus heats up. | Q34132288 | ||
Years of life lost due to obesity | Q34169086 | ||
Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis | Q37409707 | ||
The mechanisms of weight loss after bariatric surgery. | Q37442590 | ||
Gut peptides in the control of food intake | Q37442631 | ||
Obesity, inflammation, and insulin resistance--a mini-review | Q37443544 | ||
Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery | Q37446475 | ||
Targeting the CNS to treat type 2 diabetes | Q37464738 | ||
Intestinal microflora and metabolic diseases. | Q37472427 | ||
Obesity, gut hormones, and bariatric surgery. | Q37511828 | ||
The role of gut hormones in the regulation of body weight and energy homeostasis | Q37535112 | ||
Laparoscopic sleeve gastrectomy: a retrospective review of 1- and 2-year results | Q37582309 | ||
Human genetics illuminates the paths to metabolic disease | Q37634967 | ||
Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery. | Q37687612 | ||
The effect of bariatric surgery on gut hormones that alter appetite | Q37691662 | ||
Comparison of comorbidity resolution and improvement between laparoscopic sleeve gastrectomy and laparoscopic adjustable gastric banding. | Q37719313 | ||
Morbid obesity and sleeve gastrectomy: how does it work? | Q37728974 | ||
Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up | Q37761428 | ||
Bowels control brain: gut hormones and obesity | Q37768338 | ||
Metabolic syndrome, hormones, and maintenance of T cells during aging | Q37768982 | ||
Long-term results of laparoscopic sleeve gastrectomy for obesity | Q37771841 | ||
Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice | Q38313572 | ||
Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. | Q34325049 | ||
Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity | Q34330489 | ||
Anatomy and regulation of the central melanocortin system | Q34414149 | ||
Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin | Q34513044 | ||
Body-mass index and mortality in Korean men and women. | Q34559686 | ||
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial | Q34566570 | ||
Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. | Q34570264 | ||
Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. | Q34615425 | ||
Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production | Q34768998 | ||
Will all Americans become overweight or obese? estimating the progression and cost of the US obesity epidemic | Q34811626 | ||
Bariatric surgery and long-term control of morbid obesity | Q35020501 | ||
Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender | Q35592126 | ||
Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution | Q35794463 | ||
The gut and energy balance: visceral allies in the obesity wars | Q36080128 | ||
Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding | Q36259482 | ||
Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism | Q36381636 | ||
Biological, physiological, and pharmacological aspects of ghrelin | Q36447933 | ||
Ileal transposition provides insight into the effectiveness of gastric bypass surgery | Q36510310 | ||
Abdominal obesity and metabolic syndrome | Q36682671 | ||
The role of peptide YY in regulating glucose homeostasis | Q36702234 | ||
Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes | Q36755303 | ||
The lipid messenger OEA links dietary fat intake to satiety. | Q36948170 | ||
Efficacy of surgery in the management of obesity-related type 2 diabetes mellitus | Q36968398 | ||
Quality of life and alteration in comorbidity following laparoscopic adjustable gastric banding | Q37008737 | ||
Vagal sparing surgical technique but not stoma size affects body weight loss in rodent model of gastric bypass | Q37025874 | ||
Adipokines: the missing link between insulin resistance and obesity. | Q37038003 | ||
The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones | Q37095586 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
Analysis of the results of sleeve gastrectomy for morbid obesity and the role of ghrelin | Q37179040 | ||
Central and peripheral regulation of food intake and physical activity: pathways and genes | Q37204432 | ||
Global burden of obesity in 2005 and projections to 2030. | Q37209527 | ||
Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass | Q37261091 | ||
Relation of obesity to consummatory and anticipatory food reward | Q37325056 | ||
Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes | Q37345249 | ||
Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans | Q42169738 | ||
Restoration of Euglycemia and Normal Acute Insulin Response to Glucose in Obese Subjects With Type 2 Diabetes Following Bariatric Surgery | Q42440397 | ||
Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects | Q42476857 | ||
Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity | Q42634370 | ||
Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats | Q42867826 | ||
Basal plasma levels of insulin, leptin, ghrelin, and amylin do not signal adiposity in rats recovering from forced overweight | Q42953382 | ||
Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. | Q43040905 | ||
The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model | Q43075711 | ||
Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype. | Q43138002 | ||
Early postoperative insulin-resistance changes after sleeve gastrectomy | Q43241597 | ||
Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes | Q43252994 | ||
Comparison of the effects of Roux-en-Y gastric bypass and ileal transposition surgeries on food intake, body weight, and circulating peptide YY concentrations in rats. | Q43664359 | ||
The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats | Q44165158 | ||
Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects | Q44392867 | ||
Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. | Q44548921 | ||
Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. | Q44582488 | ||
Induction of control genes in intestinal gluconeogenesis is sequential during fasting and maximal in diabetes. | Q44618181 | ||
Midlife body mass index and hospitalization and mortality in older age. | Q44676822 | ||
Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease | Q44699316 | ||
Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls | Q44835010 | ||
Changes in serum ghrelin concentration following biliopancreatic diversion for obesity. | Q44848294 | ||
The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus | Q44928631 | ||
Plasma ghrelin in obesity before and after weight loss after laparoscopical adjustable gastric banding | Q44968774 | ||
The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism | Q44992657 | ||
The cholinergic system controls ghrelin release and ghrelin-induced growth hormone release in humans | Q45050687 | ||
Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin | Q45105936 | ||
Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study | Q45178354 | ||
Diabetes, obesity, and the brain | Q45232063 | ||
Laparoscopic adjustable silicone gastric banding vs laparoscopic vertical banded gastroplasty in morbidly obese patients: long-term results of a prospective randomized controlled clinical trial | Q45752787 | ||
Gastric emptying is not affected by sleeve gastrectomy--scintigraphic evaluation of gastric emptying after sleeve gastrectomy without removal of the gastric antrum | Q45811670 | ||
Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. | Q45917277 | ||
Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. | Q45986635 | ||
Effects of ileal transposition on food intake, dietary preference, and weight gain in Zucker obese rats | Q46130835 | ||
Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34. | Q46335423 | ||
Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice | Q46398531 | ||
Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study | Q46536937 | ||
Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects | Q46561401 | ||
Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial | Q46620662 | ||
Effects of load, and duration, of duodenal lipid on antropyloroduodenal motility, plasma CCK and PYY, and energy intake in healthy men. | Q46740032 | ||
Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release | Q46779245 | ||
Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein | Q46791851 | ||
Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects | Q46793748 | ||
Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal | Q46982079 | ||
Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass | Q47189295 | ||
Weight loss increases circulating levels of ghrelin in human obesity | Q47191637 | ||
Persistent correlation of ghrelin plasma levels with body mass index both in stable weight conditions and during gastric-bypass-induced weight loss | Q47209015 | ||
Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. | Q47239778 | ||
Laparoscopic sleeve gastrectomy--influence of sleeve size and resected gastric volume | Q47255556 | ||
The serial changes of ghrelin and leptin levels and their relations to weight loss after laparoscopic minigastric bypass surgery | Q47256748 | ||
Suboptimal weight loss after gastric bypass surgery: correlation of demographics, comorbidities, and insurance status with outcomes | Q47257524 | ||
Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass | Q47263805 | ||
Characterization of weight loss and weight regain mechanisms after Roux-en-Y gastric bypass in rats | Q47280174 | ||
Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment--a prospective study | Q47312330 | ||
Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people | Q47314674 | ||
Is ghrelin the culprit for weight loss after gastric bypass surgery? A negative answer | Q47330097 | ||
The effect of biliopancreatic diversion with pylorus-preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin levels: is there a hormonal contribution to the weight-reducing effect of this procedure? | Q47337924 | ||
Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters | Q47356520 | ||
Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss | Q47366382 | ||
Thirteen years of follow-up in patients with adjustable silicone gastric banding for obesity: weight loss and constant rate of late specific complications | Q47397858 | ||
Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia | Q47401795 | ||
Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats | Q47405665 | ||
Impact of laparoscopic adjustable gastric banding on plasma ghrelin, eating behaviour and body weight | Q47411049 | ||
Medical and surgical treatments for obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss | Q47448938 | ||
Two-year results on morbidity, weight loss and quality of life of sleeve gastrectomy as first procedure, sleeve gastrectomy after failure of gastric banding and gastric banding | Q47586570 | ||
Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. | Q47790721 | ||
Ghrelin: a gut-brain hormone: effect of gastric bypass surgery | Q48367505 | ||
Comparison between the results of laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass in the Indian population: a retrospective 1 year study | Q48386458 | ||
Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. | Q48457433 | ||
Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. | Q51168864 | ||
Plasma ghrelin modulation in gastric band operation and sleeve gastrectomy. | Q51439550 | ||
The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. | Q51468040 | ||
GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. | Q51481151 | ||
Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. | Q51488073 | ||
Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. | Q51495618 | ||
Peptide YY levels are elevated after gastric bypass surgery. | Q51500912 | ||
Fasting plasma ghrelin levels increase progressively after biliopancreatic diversion: one-year follow-up. | Q51519450 | ||
Ghrelin, leptin and insulin levels after restrictive surgery: a 2-year follow-up study. | Q51528154 | ||
Short-term effects of gastric bypass surgery on circulating ghrelin levels. | Q51528468 | ||
Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. | Q51749947 | ||
Body mass index and all-cause mortality in a nationwide US cohort. | Q51824712 | ||
A 10-year experience with laparoscopic gastric banding for morbid obesity: high long-term complication and failure rates. | Q52012588 | ||
Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. | Q53489244 | ||
Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. | Q53511362 | ||
Paid work increases and state benefit claims decrease after bariatric surgery. | Q53566788 | ||
The core gut microbiome, energy balance and obesity | Q57012032 | ||
Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial | Q58418687 | ||
P433 | issue | 1 | |
P921 | main subject | bariatric surgery | Q357503 |
gastrectomy | Q827390 | ||
type 2 diabetes | Q3025883 | ||
P304 | page(s) | R15-27 | |
P577 | publication date | 2011-04-06 | |
P1433 | published in | American Journal of Physiology - Regulatory, Integrative and Comparative Physiology | Q2201819 |
P1476 | title | Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery | |
P478 | volume | 301 |